We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

210 hedge funds and large institutions have $1.71B invested in Syndax Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 86 increasing their positions, 58 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 24

48% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 58

7% more funds holding

Funds holding: 196 → 210 (+14)

1.76% more ownership

Funds ownership: 102.79% → 104.55% (+1.8%)

9% more call options, than puts

Call options by funds: $16.2M | Put options by funds: $14.9M

4% less capital invested

Capital invested by funds: $1.79B → $1.71B (-$80M)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

Holders
210
Holders Change
+14
Holders Change %
+7.14%
% of All Funds
3.02%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.13%
New
38
Increased
86
Reduced
58
Closed
24
Calls
$16.2M
Puts
$14.9M
Net Calls
+$1.27M
Net Calls Change
-$2.89M

Top Buyers

1
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$16.3M
2
EAM
Eventide Asset Management
Massachusetts
+$16.3M
3
FTM
First Turn Management
California
+$11.3M
4
PCH
Polar Capital Holdings
United Kingdom
+$10.3M
5
EP
Eversept Partners
New York
+$10.2M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$48.6M
2
SI
Sofinnova Investments
California
-$28.2M
3
APM
Avidity Partners Management
Texas
-$18.2M
4
Marshall Wace
Marshall Wace
United Kingdom
-$17.4M
5
ECM
ExodusPoint Capital Management
New York
-$6.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$17.1M -$918K -44,453 -5%
CC
27
Commodore Capital
New York
$17M +$1.24M +60,000 +7%
FCMI
28
Foresite Capital Management IV
California
$16.8M – – –
Adage Capital Partners
29
Adage Capital Partners
Massachusetts
$15.7M -$876K -42,400 -5%
BNP Paribas Asset Management
30
BNP Paribas Asset Management
France
$15.2M +$16.3M +787,785 New
SI
31
Sofinnova Investments
California
$15.1M -$28.2M -1,366,670 -63%
EAM
32
Eventide Asset Management
Massachusetts
$15.1M +$16.3M +786,990 New
Bank of America
33
Bank of America
North Carolina
$14.6M -$1.96M -94,899 -11%
Northern Trust
34
Northern Trust
Illinois
$14.2M +$844K +40,877 +6%
Charles Schwab
35
Charles Schwab
California
$13.4M +$857K +41,458 +6%
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$13.2M +$7.97M +385,899 +130%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$12.9M +$994K +48,100 +8%
GIM
38
Granahan Investment Management
Massachusetts
$12.8M +$1.45M +70,379 +12%
JP Morgan Chase
39
JP Morgan Chase
New York
$12.1M -$45.5K -2,201 -0.3%
PM
40
Prosight Management
Texas
$10.7M +$52.9K +2,559 +0.5%
DCM
41
DAFNA Capital Management
California
$10.1M -$2.69M -130,372 -20%
PHP
42
Parkman Healthcare Partners
Connecticut
$9.78M -$1.91M -92,415 -15%
SVCM
43
Saturn V Capital Management
Texas
$9.66M +$1.7M +82,324 +20%
PCH
44
Polar Capital Holdings
United Kingdom
$9.63M +$10.3M +500,000 New
Ameriprise
45
Ameriprise
Minnesota
$9.36M -$720K -34,852 -7%
AG
46
Algert Global
California
$9.14M +$886K +42,870 +10%
CC
47
Casdin Capital
New York
$9.14M +$6.71M +325,000 +217%
Assenagon Asset Management
48
Assenagon Asset Management
Luxembourg
$8.97M +$766K +37,079 +9%
N
49
Nuveen
North Carolina
$8.85M -$2M -96,882 -17%
NCM
50
Nantahala Capital Management
Connecticut
$8.72M – – –
1
2
3 4 5

SNDX Hedge Fund Activity: Q3 2024 in Review

210 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2024, worth a combined $1.71B — down 4.5% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new SNDX positions and 24 closed out — a net gain of 14 holders — while 86 added to existing stakes and 58 trimmed.

The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $16.3M. The largest seller was Wellington Management Group, cutting an estimated $48.6M.

  • 210 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2024, up from 196 in Q2 2024.
  • Funds reported $1.71B of Syndax Pharmaceuticals stock for Q3 2024, down 4.5% quarter-over-quarter.
  • 38 funds opened new Syndax Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of +14 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2024 was BNP Paribas Asset Management, an estimated $16.3M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2024 was Wellington Management Group, an estimated $48.6M sold.

Based on aggregated 13F filings for Q3 2024.